Connect with us
Valneva has partnered with LimmaTech Biologics to acquire exclusive rights to develop and market Shigella4V, a vaccine candidate against shigellosis. The agreement includes an upfront payment...
In phase 3 trials, Pfizer and BioNTech's vaccine showed strong immune responses against influenza A and COVID-19 but failed to meet key objectives for influenza B....
A U.S. judge ruled that Novartis lacked grounds to suspend the launch of MSN's generic version of Entresto but ordered a temporary production halt pending Novartis'...
Baxter plans to sell its renal business by early 2025 to reduce debt, continuing its strategy of divesting subsidiaries, including a $3.857 billion sale of Biopharma...
Eli Lilly is expanding its presence with the opening of a 346,000-square-foot facility in Boston, which will house 500 scientists and the first East Coast location...
Crown Laboratories is acquiring Revance Therapeutics to expand its presence in the beauty market, offering $6.66 per share, an 89% premium. Revance, maker of the Botox...
Teva's first-half performance in Spain exceeds annual forecasts, with 2024 growth projected at 7.5%. The company has invested over €70 million in Spain since 2008, with...
Eli Lilly's first-half 2023 revenues surged 31% to $20 billion, driven by Mounjaro's $4.9 billion in sales, dominating the company’s earnings. Trulicity, in contrast, saw a...
JPMorgan Chase reduced its stake in Grifols to 3.111%, down from a previous 3.458%, with 0.256% in voting rights and 2.855% through financial instruments. This follows...
In the first half of the year, Novo Nordisk saw significant growth in sales, with Ozempic revenue up 36% to 56.685 billion crowns (€7.596 billion) and...
 |
|
 |  |
 |
|